ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on X

Kidney Week

Abstract: FR-PO0270

Serum Potassium and Phosphate Homeostasis in Patients with CKD: The CRIC Study

Session Information

Category: Bone and Mineral Metabolism

  • 502 Bone and Mineral Metabolism: Clinical

Authors

  • Kwon, Alvin Guyun, University of Texas Southwestern Department of Anesthesiology and Pain Management, Dallas, Texas, United States
  • He, Jiang, University of Texas Southwestern Department of Anesthesiology and Pain Management, Dallas, Texas, United States
  • Geng, Siyi, University of Texas Southwestern Department of Anesthesiology and Pain Management, Dallas, Texas, United States
  • Richardson, Sydney L V, Tulane University, New Orleans, Louisiana, United States
  • Wright, Layla H., Tulane University, New Orleans, Louisiana, United States
  • Lanza, Paola, University of Texas Southwestern Department of Anesthesiology and Pain Management, Dallas, Texas, United States
  • McAdams, Meredith C., University of Texas Southwestern Department of Anesthesiology and Pain Management, Dallas, Texas, United States
  • Lederer, Eleanor D., University of Texas Southwestern Department of Anesthesiology and Pain Management, Dallas, Texas, United States
  • Van Buren, Peter N., University of Texas Southwestern Department of Anesthesiology and Pain Management, Dallas, Texas, United States
  • Oygen, Suayp, Tulane University, New Orleans, Louisiana, United States
  • Erol, Halil K., Tulane University, New Orleans, Louisiana, United States
  • Gorrepati, Geetika, Tulane University, New Orleans, Louisiana, United States
  • Batuman, Vecihi, Tulane University, New Orleans, Louisiana, United States
  • Moe, Orson W., University of Texas Southwestern Department of Anesthesiology and Pain Management, Dallas, Texas, United States
  • Hamm, L. Lee, Tulane University, New Orleans, Louisiana, United States
  • Chen, Jing, University of Texas Southwestern Department of Anesthesiology and Pain Management, Dallas, Texas, United States
Background

Increased serum phosphorus is prevalent in CKD and linked to higher mortality risk. Small feeding studies reported that potassium supplementation raises plasma phosphate levels but may decrease fibroblast growth factor 23 (FGF23) without affecting parathyroid hormone (PTH) in non-CKD individuals. This study investigates the associations of serum potassium with serum phosphorus, calcium, FGF23, alkaline phosphatase (ALP), and PTH in a large cohort of CKD patients.

Methods

This analysis included 3,865 participants with CKD from the Chronic Renal Insufficiency Cohort (CRIC) Study after excluding 134 participants with missing data. Linear regression assessed cross-sectional associations of serum potassium with serum phosphorus, calcium, FGF23, ALP, and PTH, adjusting for age, sex, black, center-sites, education, current smoker, calories/day, diabetes status, cardiovascular disease, body mass index, HbA1c, eGFR, use of ACE inhibitors, ARB, and vitamin D, 24-hour urine sodium, and 24-hour urine creatinine.

Results

The average age of participants was 58 years, and the mean eGFR was 44 mL/min/1.73 m^2. After multiple adjustments, serum potassium was significantly and positively associated with serum phosphate and calcium (Table). However, serum potassium was not significantly associated with PTH, FGF23, or ALP levels.

Conclusion

In patients with CKD, elevated circulating potassium is independently linked to higher phosphate and calcium, but not to PTH, FGF23, and ALP, suggesting circulating potassium may be linked to phosphate and calcium metabolism in CKD. Further research is needed to confirm these findings.

Association of a One-SD (0.53 mmol/L) Increase in Serum Potassium with Significant Phosphate-Related Biomarkers
OutcomesMultivariable adjusted
β Coefficient (95% CI)P-value
Serum Phosphate (mg/dL)0.09 (0.07, 0.11)<0.001
Serum Calcium (mg/dL)0.05 (0.03, 0.07)<0.001

Digital Object Identifier (DOI)